Ipca Labs' board approves acquisition of over 26% stake in Lyka Labs

Lyka Labs is engaged in the manufacturing and marketing of injectables, lyophilized injectables and topical formulations



New Delhi
Ipca Laboratories on Wednesday said that its board of directors has approved the acquisition of 26.574% of the paid-up share capital of Lyka Labs for a cash consideration of Rs

Also Read

Lyka Labs hits 5% upper circuit after Ipca buys 1 mn shares via bulk deals

3 stock ideas by Osho Krishan of Anand Rathi: Buy Havells, Ipca Labs

Laurus Labs hits record high; rallies 17% in 7 days post Q1 results

Lack of valuation comfort may limit gains in Divi's Laboratories stock

New Reliance Industries' partly paid shares commence trading on NSE

Thermax bags order worth Rs 830 crore to set up FGD systems

IndusInd Bank clarifies on appointment of BFIL executives by SSFL

Park+, app for car users, raises $25 mn from Sequoia, Matrix, Epiq

Licious starts 'everyday vesting, anytime liquidation' ESOP for employees

Dozen Indian IPOs now under extra investor scrutiny after Paytm debacle

First Published: Nov 24 2021 | 2:58 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to